Status:
COMPLETED
Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions:
Coronavirus Disease 2019 )COVID-19)
Eligibility:
All Genders
65+ years
Phase:
PHASE2
PHASE3
Brief Summary
Older age is an independent poor outcome predictor among COVID-19 hospitalized patients . Among 72,314 COVID-19 cases, case fatality rate (CFR) was 2.3% in total population, 8% in people aged 70 to 79...
Eligibility Criteria
Inclusion
- Age ≥ 65
- pneumonia at CT scan
- PaO2/FiO2 ≥300 mmHg
- Presence of one or more comorbidities (consider the list provided in Appendix A)
- Signed informed consent
Exclusion
- Age \< 65
- PaO2/FiO2 \< 300 mmHg
- pending cardiopulmonary arrest
- refusal to blood product transfusions
- Severe IgA deficiency
- any life-threatening comorbidity or any other medical condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion
Key Trial Info
Start Date :
May 27 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 26 2021
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT04374526
Start Date
May 27 2020
End Date
May 26 2021
Last Update
May 28 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione Policlinico Universitario A. Gemelli IRCCS
Roma, RM, Italy, 00168
2
Ospedale SS Annunziata
Chieti, Italy, 66100
3
Istituto Nazionale Malattie Infettive Lazzaro Spallanzani
Rome, Italy, 00149